Michaela Jeong
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 16, 2024
GTSE1-driven ZEB1 stabilization promotes pulmonary fibrosis through the epithelial-to-mesenchymal transition.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 14, 2024
Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics.
Journal: Biomaterials research
Published: December 03, 2023
Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics.
Journal: Experimental & molecular medicine
Published: April 24, 2023
Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications.
Journal: Advanced drug delivery reviews
Published: March 29, 2023
Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety.
Journal: Bioengineering & translational medicine
Published: October 28, 2022
In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.
Journal: Science advances
Published: January 21, 2022
Protein-RNA interaction guided chemical modification of Dicer substrate RNA nanostructures for superior in vivo gene silencing.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: May 24, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026